4.1 Article

Targeting a Uniquely Nonspecific Prenyl Synthase with Bisphosphonates to Combat Cryptosporidiosis

期刊

CHEMISTRY & BIOLOGY
卷 15, 期 12, 页码 1296-1306

出版社

CELL PRESS
DOI: 10.1016/j.chembiol.2008.10.017

关键词

-

资金

  1. Canadian Institutes for Health Research
  2. Canadian Foundation for Innovation
  3. Genome Canada through the Ontario Genomics Institute, GIaxoSmithKline
  4. Knut and Alice Wallenberg Foundation
  5. Ontario Innovation Trust
  6. Ontario Ministry for Research and Innovation
  7. Merck Co. Inc.
  8. Novartis Research Foundation
  9. Petrus and Augusta Hedlund's Foundation
  10. Swedish Agency for Innovation Systems
  11. Swedish Foundation for Strategic Research
  12. Wellcome Trust
  13. McLaughlin Centre of Molecular Medicine
  14. US NIH [GM074942]

向作者/读者索取更多资源

Cryptosporidiosis is a neglected disease without a wholly effective drug. We present a study demonstrating nitrogen-containing bisphosphonates (N-BPs) to be capable of inhibiting Cryptosporidium parvum at low micromolar concentrations in infected MDCK cells. Predictably, the mechanism of action is based on inhibition of biosynthesis of isoprenoids but the target enzyme is unexpectedly a distinctive C. parvum enzyme dubbed nonspecific polyprenyl pyrophosphate synthase (CpNPPPS). This enzyme produces various isoprenoid products larger than FPP and is inhibited by N-BPs at subnanomolar concentrations. It is part of an isoprenoid pathway in Cryptosporidium distinctly different from other organisms. The proposed mechanism of action is corroborated by crystal structures of the enzyme with risedronate and zoledronate bound showing how this enzyme's unique chain length determinant region enables it to accommodate larger substrates and products. These results, combined with existing data on their clinical use, demonstrate that N-BPs are very promising anticryptosporidial drug candidates.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据